Citations (105)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Farzad Allameh, Abbas Basiri, Mohammadreza Razzaghi, Amir reza Abedi, Morteza Fallah-karkan, Saleh Ghiasy, Seyyed Mohammad Hosseininia & Saeed Montazeri. (2020) Clinical Efficacy of Transurethral Resection of the Prostate Combined with Oral Anticholinergics or Botulinum Toxin – A Injection to Treat Benign Prostatic Hyperplasia with Overactive Bladder: A Case–Control Study. Clinical Pharmacology: Advances and Applications 12, pages 75-81.
Read now
Read now
Richard Flint, Angie Rantell & Linda Cardozo. (2018) AbobotulinumtoxinA for the treatment of overactive bladder. Expert Opinion on Biological Therapy 18:10, pages 1005-1013.
Read now
Read now
Todd A. Linsenmeyer. (2013) Use of botulinum toxin in individuals with neurogenic detrusor overactivity: State of the art review. The Journal of Spinal Cord Medicine 36:5, pages 402-419.
Read now
Read now
Apostolos Apostolidis. (2011) Pharmacotherapy for overactive bladder: minimally invasive treatment – botulinum toxins. Expert Opinion on Pharmacotherapy 12:7, pages 1029-1039.
Read now
Read now
Articles from other publishers (101)
Cyrille Guillot-Tantay & Véronique Phé. (2024) Comment je prescris le Dysport® (abobotulinumtoxin A). Progrès en Urologie - FMC 34:2, pages F53-F55.
Crossref
Crossref
Meryam El Issaoui, Sophia Elissaoui, Marlene Elmelund & Niels Klarskov. (2023) Bleeding risk in female patients undergoing intravesical injection of onabotulinumtoxinA for overactive bladder: a Danish retrospective cohort study. International Urogynecology Journal 34:10, pages 2581-2585.
Crossref
Crossref
Martin C. Michel, Linda Cardozo, Christopher J. Chermansky, Francisco Cruz, Yasuhiko Igawa, Kyu-Sung Lee, Arun Sahai, Alan J. Wein & Karl-Erik Andersson. (2023) Current and Emerging Pharmacological Targets and Treatments of Urinary Incontinence and Related Disorders. Pharmacological Reviews 75:4, pages 554-674.
Crossref
Crossref
Pierre Denys, Juan Carlos Castaño Botero, Ricardo Luis Vita Nunes, Barton Wachs, Cristiano Mendes Gomes, Grigory Krivoborodov, Le Mai Tu, Giulio Del‐Popolo, Catherine Thompson, Claire Vilain, Magali Volteau & Michael Kennelly. (2022) AbobotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity regardless of spinal cord injury or multiple sclerosis etiology: Pooled analysis of two phase III randomized studies (CONTENT1 and CONTENT2). Neurourology and Urodynamics 42:1, pages 153-167.
Crossref
Crossref
Rawa Bapir, Kamran Hassan Bhatti, Ahmed Eliwa, Herney Andrés García-Perdomo, Nazim Gherabi, Derek Hennessey, Vittorio Magri, Panagiotis Mourmouris, Adama Ouattara, Gianpaolo Perletti, Joseph Philipraj, Konstantinos Stamatiou, Alberto Trinchieri & Noor Buchholz. (2022) Efficacy of overactive neurogenic bladder treatment: A systematic review of randomized controlled trials. Archivio Italiano di Urologia e Andrologia 94:4, pages 492-506.
Crossref
Crossref
Michael Kennelly, Francisco Cruz, Sender Herschorn, Paul Abrams, Kadir Onem, Viktor Kibanov Solomonov, Elena del Rosario Figueroa Coz, Andrei Manu-Marin, Antonella Giannantoni, Catherine Thompson, Claire Vilain, Magali Volteau & Pierre Denys. (2022) Efficacy and Safety of AbobotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity Incontinence Performing Regular Clean Intermittent Catheterization: Pooled Results from Two Phase 3 Randomized Studies (CONTENT1 and CONTENT2). European Urology 82:2, pages 223-232.
Crossref
Crossref
Kevin R. Patel, Ashley Riddle, Matthew Arffa & S. Tyler Hollmig. (2022) A review on the history, use, and new developments of abobotulinumtoxinA (Dysport). Dermatological Reviews 3:4, pages 197-210.
Crossref
Crossref
Sheng‐Fu Chen & Hann‐Chorng Kuo. (2022) Interventional management and surgery of neurogenic lower urinary tract dysfunction in patients with chronic spinal cord injury: A urologist's perspective. LUTS: Lower Urinary Tract Symptoms 14:3, pages 132-139.
Crossref
Crossref
Yuan-Hong Jiang, Sheng-Fu Chen & Hann-Chorng Kuo. (2020) Frontiers in the Clinical Applications of Botulinum Toxin A as Treatment for Neurogenic Lower Urinary Tract Dysfunction. International Neurourology Journal 24:4, pages 301-312.
Crossref
Crossref
R. Corey O'Connor, Dane P. Johnson & Michael L. Guralnick. (2020) Intradetrusor botulinum toxin injections (300 units) for the treatment of poorly compliant bladders in patients with adult neurogenic lower urinary tract dysfunction. Neurourology and Urodynamics 39:8, pages 2322-2328.
Crossref
Crossref
Natalia Hernandez & Rose Khavari. 2020. Urological Care for Patients with Progressive Neurological Conditions. Urological Care for Patients with Progressive Neurological Conditions
117
125
.
Elizabeth Lucas. (2019) Medical Management of Neurogenic Bladder for Children and Adults: A Review. Topics in Spinal Cord Injury Rehabilitation 25:3, pages 195-204.
Crossref
Crossref
Danielle de Sá Dantas Bezerra, Luis Gustavo Morato de Toledo, Silvia da Silva Carramão, Antonio F. Silva Rodrigues, Roger Dmockowski & Antonio P. F. Auge. (2018) A prospective randomized clinical trial comparing two doses of AbobotulinumtoxinA for idiopathic overactive bladder. Neurourology and Urodynamics 38:2, pages 660-667.
Crossref
Crossref
Adam Althaus & Anurag K. Das. 2019. Smith's Textbook of Endourology. Smith's Textbook of Endourology
1775
1783
.
Yu-Cheng Chou, Yuan-Hong Jiang, Tomor Harnod, Hsu-Tung Lee & Hann-Chorng Kuo. (2019) Stroke and Lower Urinary Tract Symptoms. Urological Science 30:1, pages 8-13.
Crossref
Crossref
João Silva & Francisco Cruz. 2019. Neurourology. Neurourology
291
298
.
Giovanni Palleschi, Giovanni Mosiello, Valerio Iacovelli, Stefania Musco, Giulio Del Popolo, Antonella Giannantoni, Antonio Carbone, Roberto Carone, Andrea Tubaro, Mario De Gennaro, Antonio Marte & Enrico Finazzi Agrò. (2017) Adolescence transitional care in neurogenic detrusor overactivity and the use of OnabotulinumtoxinA: A clinical algorithm from an Italian consensus statement. Neurourology and Urodynamics 37:3, pages 904-915.
Crossref
Crossref
Yunliang Gao, Melissa Sanford, Francisco Cruz & David Ginsberg. 2018. Neuro-Urology. Neuro-Urology
387
404
.
Jacques Corcos & Mikolaj PrzydaczJacques Corcos & Mikolaj Przydacz. 2018. Consultation in Neurourology. Consultation in Neurourology
77
113
.
Saman Shafaat Talab, Hossein Sadeghi-Nejad & Patricia E. Gilhooly. 2018. Botulinum Toxin Treatment in Clinical Medicine. Botulinum Toxin Treatment in Clinical Medicine
49
65
.
Florie Bottet, Benoit Peyronnet, Romain Boissier, Bénédicte Reiss, Jean G. Previnaire, Andrea Manunta, Jacques Kerdraon, Alain Ruffion, Loïc Lenormand, Brigitte Perrouin Verbe, Sarah Gaillet, Xavier Gamé & Gilles Karsenty. (2017) Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed. Neurourology and Urodynamics 37:1, pages 291-297.
Crossref
Crossref
Nachiketh Soodana Prakash, Diana M. Lopategui & Christopher Gomez. (2017) Changes in Management of Poorly Compliant Bladder in Botulinum Toxin A Era. Current Urology Reports 18:8.
Crossref
Crossref
Hejia Yuan, Yuanshan Cui, Jitao Wu, Peng Peng, Xujie Sun & Zhenli Gao. (2017) Efficacy and Adverse Events Associated With Use of OnabotulinumtoxinA for Treatment of Neurogenic Detrusor Overactivity: A Meta-Analysis. International Neurourology Journal 21:1, pages 53-61.
Crossref
Crossref
Benoit Peyronnet, Evelyne Castel‐Lacanal, Mathieu Roumiguie, Lucie Even, Philippe Marque, Michel Soulié, Pascal Rischmann & Xavier Game. (2016) Intradetrusor injections of onabotulinum toxin A (Botox®) 300 U or 200 U versus abobotulinum toxin A (Dysport®) 750 U in the management of neurogenic detrusor overactivity: A case control study. Neurourology and Urodynamics 36:3, pages 734-739.
Crossref
Crossref
Jarosław Sławek & Mariusz Madaliński. 2017. Nonmotor Parkinson’s: The Hidden Face - Management and the Hidden Face of Related Disorders. Nonmotor Parkinson’s: The Hidden Face - Management and the Hidden Face of Related Disorders
1111
1142
.
Tao Cheng, Wei-bing Shuang, Dong-dong Jia, Min Zhang, Xu-nan Tong, Wei-dong Yang, Xu-ming Jia & Shuo Li. (2016) Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLOS ONE 11:7, pages e0159307.
Crossref
Crossref
Véronique Phé, Emmanuel Chartier–Kastler & Jalesh N. Panicker. (2016) Management of neurogenic bladder in patients with multiple sclerosis. Nature Reviews Urology 13:5, pages 275-288.
Crossref
Crossref
Benoit Peyronnet, Mathieu Roumiguié, Evelyne Castel-Lacanal, Julien Guillotreau, Philippe Marque, Pascal Rischmann & Xavier Gamé. (2015) Efficacy and safety of the first and repeated intradetrusor injections of abobotulinum toxin A 750 U for treating neurological detrusor overactivity. World Journal of Urology 34:5, pages 755-761.
Crossref
Crossref
David Moore, Joshua Cohn & Roger Dmochowski. (2016) Use of Botulinum Toxin A in the Treatment of Lower Urinary Tract Disorders: A Review of the Literature. Toxins 8:4, pages 88.
Crossref
Crossref
Benoit Peyronnet, Mathieu Roumiguié, Evelyne Castel-Lacanal, Julien Guillotreau, Bernard Malavaud, Philippe Marque, Pascal Rischmann & Xavier Gamé. (2016) Preliminary results of botulinum toxin A switch after first detrusor injection failure as a treatment of neurogenic detrusor overactivity. Neurourology and Urodynamics 35:2, pages 267-270.
Crossref
Crossref
Vincenzo Li Marzi, Jacopo Frizzi, Matteo Bonifazi & Giulio Del Popolo. 2016. Functional Urologic Surgery in Neurogenic and Oncologic Diseases. Functional Urologic Surgery in Neurogenic and Oncologic Diseases
171
186
.
Amélie Huynh Le Maux, Bernadette Pignol, Delphine Behr-Roussel, Jean-Luc Blachon, Pierre-Etienne Chabrier, Sandrine Compagnie, Philippe Picaut, Jacques Bernabé, François Giuliano & Pierre Denys. (2015) Does Reduction of Number of Intradetrusor Injection Sites of aboBoNTA (Dysport®) Impact Efficacy and Safety in a Rat Model of Neurogenic Detrusor Overactivity?. Toxins 7:12, pages 5462-5471.
Crossref
Crossref
B. Peyronnet, S. Sanson, G. Amarenco, E. Castel-Lacanal, E. Chartier-Kastler, K. Charvier, M. Damphousse, P. Denys, M. de Seze, G. Egon, A. Even, V. Forin, G. Karsenty, J. Kerdraon, L. le Normand, C.-M. Loche, A. Manunta, P. Mouracade, V. Phe, J.-G. Previnaire, A. Ruffion, C. Saussine, B. Schurch & X. Game. (2015) Définition et prise en charge de l’échec d’une première injection de toxine botulique Botox® 200 U pour hyperactivité détrusorienne neurogène : résultats de l’enquête DETOX. Progrès en Urologie 25:17, pages 1219-1224.
Crossref
Crossref
Richard S Nicholas, Tim Friede, Sally Hollis & Carolyn A Young. (2015) Anticholinergics for urinary symptoms in multiple sclerosis. Cochrane Database of Systematic Reviews 2015:6.
Crossref
Crossref
Claire S. Riley & Wendy Vargas. (2015) Multiple Sclerosis in the Elderly: Considerations in the Geriatric Population for Diagnosis and Management. Current Geriatrics Reports 4:2, pages 131-141.
Crossref
Crossref
Gabriele Gaziev, Valerio Iacovelli, Luca Topazio, Daniele Bianchi & Enrico Finazzi Agrò. (2015) New treatments for neurogenic detrusor overactivity. Clinical Investigation 5:5, pages 519-528.
Crossref
Crossref
Rui Zhang, Yongteng Xu, Shengping Yang, Hui Liang, Yunxin Zhang & Yali Liu. (2015) OnabotulinumtoxinA for neurogenic detrusor overactivity and dose differences: a systematic review. International braz j urol 41:2, pages 207-219.
Crossref
Crossref
Joel Hillelsohn & Gerald Matthews. (2015) Editorial Comment to Botulinum toxin A injection for the treatment of neurogenic detrusor overactivity secondary to spinal cord injury: Multi‐institutional experience in Japan. International Journal of Urology 22:3, pages 310-310.
Crossref
Crossref
Atsushi Sengoku, Kikuo Okamura, Yasusuke Kimoto, Takatoshi Ogawa, Takashige Namima, Tomonori Yamanishi, Teruhiko Yokoyama, Hironobu Akino & Yoshiko Maeda. (2014)
Botulinum toxin
A
injection for the treatment of neurogenic detrusor overactivity secondary to spinal cord injury: Multi‐institutional experience in
J
apan
. International Journal of Urology 22:3, pages 306-309.
Crossref
Crossref
Apostolos Apostolidis. 2015. Overactive Bladder. Overactive Bladder
164
188
.
Jalesh N. Panicker & Clare J. Fowler. 2015. Neurology of Sexual and Bladder Disorders. Neurology of Sexual and Bladder Disorders
371
381
.
Brigitte Schurch, Cécile Tawadros & Stefano Carda. 2015. Neurology of Sexual and Bladder Disorders. Neurology of Sexual and Bladder Disorders
247
267
.
Hann-Chorng Kuo, Sung-Lang Chen, Chieh-Lung Chou, Yao-Chi Chuang, Yu-Hui Huang, Yung-Shun Juan, Wei-Ching Lee, Chun-Hou Liao, Yao-Chou Tsai, Yun-An Tsai & Chung-Cheng Wang. (2014) Clinical guidelines for the diagnosis and management of neurogenic lower urinary tract dysfunction. Tzu Chi Medical Journal 26:3, pages 103-113.
Crossref
Crossref
B. Schurch & S. Carda. (2014) OnabotulinumtoxinA and multiple sclerosis. Annals of Physical and Rehabilitation Medicine 57:5, pages 302-314.
Crossref
Crossref
Francisco Cruz & Victor Nitti. (2014) Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB). Neurourology and Urodynamics 33:S3.
Crossref
Crossref
N Yıldız, Y Akkoç, B Erhan, B Gündüz, B Yılmaz, R Alaca, H Gök, K Köklü, M Ersöz, E Çınar, H Karapolat, N Çatalbaş, A N Bardak, I Turna, Y Demir, S Güneş, E Alemdaroğlu & H Tunç. (2014) Neurogenic bladder in patients with traumatic spinal cord injury: treatment and follow-up. Spinal Cord 52:6, pages 462-467.
Crossref
Crossref
Hann-Chorng Kuo, Sung-Lang Chen, Chieh-Lung Chou, Yao-Chi Chuang, Yu-Hui Huang, Yung-Shun Juan, Wei-Ching Lee, Chun-Hou Liao, Yao-Chou Tsai, Yun-An Tsai & Chung-Cheng Wang. (2014) Taiwanese Continence Society clinical guidelines for diagnosis and management of neurogenic lower urinary tract dysfunction. Urological Science 25:2, pages 35-41.
Crossref
Crossref
Ahmed Toosy, Olga Ciccarelli & Alan Thompson. 2014. Multiple Sclerosis and Related Disorders. Multiple Sclerosis and Related Disorders
513
562
.
Dirk Dressler. 2014. Clinical Applications of Botulinum Neurotoxin. Clinical Applications of Botulinum Neurotoxin
95
121
.
Arun Sahai, Jai Seth, Muhammed Shamim Khan & Prokar Dasgupta. 2014. Minimally Invasive Therapy for Urinary Incontinence and Pelvic Organ Prolapse. Minimally Invasive Therapy for Urinary Incontinence and Pelvic Organ Prolapse
135
154
.
Chung-Cheng Wang & Hann-Chorng Kuo. (2013) Satisfaction and quality of life issues in patients receiving urethral botulinum toxin A injections for detrusor sphincter dyssynergia and detrusor botulinum toxin A injections for neurogenic detrusor overactivity. Tzu Chi Medical Journal 25:4, pages 195-199.
Crossref
Crossref
R. Caremel, P. Grise & J. Corcos. (2013) Principios de acción e indicaciones de la toxina botulínica en el tratamiento de la hiperactividad vesical del adulto. EMC - Urología 45:4, pages 1-12.
Crossref
Crossref
Gael J. Yonnet, Anette S. Fjeldstad, Noel G. Carlson & John W. Rose. (2013) Advances in the Management of Neurogenic Detrusor Overactivity in Multiple Sclerosis. International Journal of MS Care 15:2, pages 66-72.
Crossref
Crossref
Michael B. Chancellor, Elie Elovic, Alberto Esquenazi, Markus Naumann, Karen R. Segal, Giampietro Schiavo, Christopher P. Smith & Anthony B. Ward. (2013) Evidence-based review and assessment of botulinum neurotoxin for the treatment of urologic conditions. Toxicon 67, pages 129-140.
Crossref
Crossref
Dirk Dressler. (2012) Botulinum toxin therapy: its use for neurological disorders of the autonomic nervous system. Journal of Neurology 260:3, pages 701-713.
Crossref
Crossref
Markus Naumann, Lee Ming Boo, Alan H. Ackerman & Conor J. Gallagher. (2012) Immunogenicity of botulinum toxins. Journal of Neural Transmission 120:2, pages 275-290.
Crossref
Crossref
Amar Mohee, Ayisha Khan, Neil Harris & Ian Eardley. (2012)
Long‐term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (
OAB
)
. BJU International 111:1, pages 106-113.
Crossref
Crossref
Katsuya Hikita, Masashi Honda, Bunya Kawamoto, Tsounapi Panagiota, Seiya Inoue, Nobuyuki Hinata, Kuniyasu Muraoka & Atsushi Takenaka. (2012)
Botulinum toxin type
A
injection for neurogenic detrusor overactivity: Clinical outcome in
J
apanese patients
. International Journal of Urology 20:1, pages 94-99.
Crossref
Crossref
Jalesh N. Panicker, Marianne De Sèze & Clare J. Fowler. 2013. Neurological Rehabilitation. Neurological Rehabilitation
209
220
.
Adam B. Hollander & Ricardo R. Gonzalez. (2012) Evaluation and Management of Urgency and Urge Urinary Incontinence in Men. Current Bladder Dysfunction Reports 7:3, pages 230-234.
Crossref
Crossref
Teruhiko Yokoyama, Michael B Chancellor, Keiji Oguma, Yumiko Yamamoto, Tomonori Suzuki, Hiromi Kumon & Atsushi Nagai. (2012) Botulinum toxin type A for the treatment of lower urinary tract disorders. International Journal of Urology 19:3, pages 202-215.
Crossref
Crossref
Altaf Mangera & Christopher R. Chapple. (2012) Botulinum toxin therapy for the management of lower urinary tract symptoms – has this come of age?. Drug Discovery Today: Therapeutic Strategies 9:1, pages e35-e39.
Crossref
Crossref
Mehrdad Alemozaffar & Anurag K. Das. 2012. Smith's Textbook of Endourology. Smith's Textbook of Endourology
1625
1632
.
James B Duthie, Michael Vincent, G Peter Herbison, David Iain Wilson & Don Wilson. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Arun Sahai, Eduardo Cortes, Jai Seth, Muhammad Shamim Khan, Jalesh Panicker, Cornelius Kelleher, Thomas M. Kessler, Clare J. Fowler & Prokar Dasgupta. (2011) Neurogenic Detrusor Overactivity in Patients With Spinal Cord Injury: Evaluation and Management. Current Urology Reports 12:6, pages 404-412.
Crossref
Crossref
Altaf Mangera, Karl-Erik Andersson, Apostolos Apostolidis, Chris Chapple, Prokar Dasgupta, Antonella Giannantoni, Stavros Gravas & Stephan Madersbacher. (2011) Contemporary Management of Lower Urinary Tract Disease With Botulinum Toxin A: A Systematic Review of Botox (OnabotulinumtoxinA) and Dysport (AbobotulinumtoxinA). European Urology 60:4, pages 784-795.
Crossref
Crossref
Angelo E. Gousse, Prashanth Kanagarajah, Rajinikanth Ayyathurai, Priyanka Handa, Nikita Dabas & Christopher S. Gomez. (2011) Repeat Intradetrusor Injections of Onabotulinum Toxin A for Refractory Idiopathic Overactive Bladder Patients. Female Pelvic Medicine & Reconstructive Surgery 17:5, pages 253-257.
Crossref
Crossref
Sender Herschorn, Jerzy Gajewski, Karen Ethans, Jacques Corcos, Kevin Carlson, Gregory Bailly, Robert Bard, Luc Valiquette, Richard Baverstock, Lesley Carr & Sidney Radomski. (2011) Efficacy of Botulinum Toxin A Injection for Neurogenic Detrusor Overactivity and Urinary Incontinence: A Randomized, Double-Blind Trial. Journal of Urology 185:6, pages 2229-2235.
Crossref
Crossref
Ana Charrua, António Avelino & Francisco Cruz. 2011. Urinary Tract. Urinary Tract
345
374
.
Michael B. Chancellor & Christopher P. SmithMichael B. Chancellor & Christopher P. Smith. 2011. Botulinum Toxin in Urology. Botulinum Toxin in Urology
29
59
.
Alan J Thompson, Ahmed T Toosy & Olga Ciccarelli. (2010) Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions. The Lancet Neurology 9:12, pages 1182-1199.
Crossref
Crossref
Catherine M. Dalton, Giuseppi Preziosi, Shahid Khan & Marianne de Sèze. 2010. Pelvic Organ Dysfunction in Neurological Disease. Pelvic Organ Dysfunction in Neurological Disease
220
240
.
. 2010. Pelvic Organ Dysfunction in Neurological Disease. Pelvic Organ Dysfunction in Neurological Disease
167
306
.
Apostolos Apostolidis, Soumendra Nath Datta, Xavier Gamé & Shahid Khan. 2010. Pelvic Organ Dysfunction in Neurological Disease. Pelvic Organ Dysfunction in Neurological Disease
89
111
.
. 2010. Pelvic Organ Dysfunction in Neurological Disease. Pelvic Organ Dysfunction in Neurological Disease
61
166
.
John T. Stoffel. (2010) Contemporary Management of the Neurogenic Bladder for Multiple Sclerosis Patients. Urologic Clinics of North America 37:4, pages 547-557.
Crossref
Crossref
Marc C. Smaldone, Benjamin T. Ristau & Wendy W. Leng. (2010) Botulinum Toxin Therapy for Neurogenic Detrusor Overactivity. Urologic Clinics of North America 37:4, pages 567-580.
Crossref
Crossref
Philippe Grise, Alain Ruffion, Pierre Denys, Guy Egon & Emmanuel Chartier Kastler. (2010) Efficacy and Tolerability of Botulinum Toxin Type A in Patients with Neurogenic Detrusor Overactivity and Without Concomitant Anticholinergic Therapy: Comparison of Two Doses. European Urology 58:5, pages 759-766.
Crossref
Crossref
Mario Habek, Arnon Karni, Yakov Balash & Tanya Gurevich. (2010) The place of the botulinum toxin in the management of multiple sclerosis. Clinical Neurology and Neurosurgery 112:7, pages 592-596.
Crossref
Crossref
Jalesh N PanickerMarianne de Sèze & Clare J Fowler. (2010) Rehabilitation in Practice: Neurogenic lower urinary tract dysfunction and its management. Clinical Rehabilitation 24:7, pages 579-589.
Crossref
Crossref
Athanassios Oeconomou & Apostolos Apostolidis. (2010) Current Status of Botulinum Toxin for Neurogenic Bladder Dysfunction. Current Bladder Dysfunction Reports 5:2, pages 87-97.
Crossref
Crossref
Thomas M. Kessler, Shahid Khan, Jalesh N. Panicker, Sohier Elneil, Sebastian Brandner, Clare J. Fowler & Alexander Roosen. (2010) In the Human Urothelium and Suburothelium, Intradetrusor Botulinum Neurotoxin Type A Does Not Induce Apoptosis: Preliminary Results. European Urology 57:5, pages 879-883.
Crossref
Crossref
Xavier Gamé, Clare J. Fowler & Jalesh N. Panicker. (2010) Neuropathic bladder dysfunction. Trends in Urology, Gynaecology & Sexual Health 15:1, pages 23-28.
Crossref
Crossref
John Lazarus. (2009) Intravesical oxybutynin in the pediatric neurogenic bladder. Nature Reviews Urology 6:12, pages 671-674.
Crossref
Crossref
Jalesh Panicker & Collette Haslam. (2009) Lower urinary tract dysfunction in MS: management in the community. British Journal of Community Nursing 14:11, pages 474-480.
Crossref
Crossref
C J Fowler, J N Panicker, M Drake, C Harris, S C W Harrison, M Kirby, M Lucas, N Macleod, J Mangnall, A North, B Porter, S Reid, N Russell, K Watkiss & M Wells. (2009) A UK consensus on the management of the bladder in multiple sclerosis. Postgraduate Medical Journal 85:1008, pages 552-559.
Crossref
Crossref
Carlos Martins da Silva & Francisco Cruz. (2009) Has botulinum toxin therapy come of age: what do we know, what do we need to know, and should we use it?. Current Opinion in Urology 19:4, pages 347-352.
Crossref
Crossref
Manfred Stöhrer, Bertil Blok, David Castro-Diaz, Emanuel Chartier-Kastler, Giulio Del Popolo, Guus Kramer, Jürgen Pannek, Piotr Radziszewski & Jean-Jacques Wyndaele. (2009) EAU Guidelines on Neurogenic Lower Urinary Tract Dysfunction. European Urology 56:1, pages 81-88.
Crossref
Crossref
Arun Sahai, Christopher Dowson, Mohammad S. Khan & Prokar Dasgupta. (2009) Improvement in quality of life after botulinum toxin‐A injections for idiopathic detrusor overactivity: results from a randomized double‐blind placebo‐controlled trial. BJU International 103:11, pages 1509-1515.
Crossref
Crossref
Alexander Roosen, Soumendra N. Datta, Rasheda A. Chowdhury, Pravina M. Patel, Vinay Kalsi, Sohier Elneil, Prokar Dasgupta, Thomas M. Kessler, Shahid Khan, Jalesh Panicker, Christopher H. Fry, Sebastian Brandner, Clare J. Fowler & Apostolos Apostolidis. (2009) Suburothelial Myofibroblasts in the Human Overactive Bladder and the Effect of Botulinum Neurotoxin Type A Treatment. European Urology 55:6, pages 1440-1449.
Crossref
Crossref
Shahid Khan, Thomas M. Kessler, Apostolos Apostolidis, Vinay Kalsi, Jalesh Panicker, Alexander Roosen, Gwen Gonzales, Collete Haslam, Sohier Elneil, Clare J. Fowler & Prokar Dasgupta. (2009) What a Patient With Refractory Idiopathic Detrusor Overactivity Should Know About Botulinum Neurotoxin Type A Injection. Journal of Urology 181:4, pages 1773-1778.
Crossref
Crossref
Arun Sahai, Philippa Sangster, Vinay Kalsi, Mohammad S. Khan, Clare J. Fowler & Prokar Dasgupta. (2009) Assessment of urodynamic and detrusor contractility variables in patients with overactive bladder syndrome treated with botulinum toxin‐A: is incomplete bladder emptying predictable?. BJU International 103:5, pages 630-634.
Crossref
Crossref
Richard S Nicholas, Tim Friede, Sally Hollis & Carolyn A Young. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Apostolos Apostolidis, Prokar Dasgupta, Pierre Denys, Sohier Elneil, Clare J. Fowler, Antonella Giannantoni, Gilles Karsenty, Heinrich Schulte-Baukloh, Brigitte Schurch & Jean-Jacques Wyndaele. (2009) Recommendations on the Use of Botulinum Toxin in the Treatment of Lower Urinary Tract Disorders and Pelvic Floor Dysfunctions: A European Consensus Report. European Urology 55:1, pages 100-120.
Crossref
Crossref
Brigitte Schurch & Dennis Dykstra. 2009. Botulinum Toxin. Botulinum Toxin
240
256
.
K J Eccleston & P D Woolley. (2008) Botulinum toxin for urogenital conditions. International Journal of STD & AIDS 19:12, pages 797-799.
Crossref
Crossref
Paulo Dinis & Francisco Cruz. (2008) Intravesical strategies to manage the neurogenic bladder. Current Bladder Dysfunction Reports 3:3, pages 133-139.
Crossref
Crossref
E.J. Maher & A. Denton. (2008) Survivorship, Late Effects and Cancer of the Cervix. Clinical Oncology 20:6, pages 479-487.
Crossref
Crossref
Ann T Hanna-Mitchell & Lori A Birder. (2008) New insights into the pharmacology of the bladder. Current Opinion in Urology 18:4, pages 347-352.
Crossref
Crossref
Hann-Chorng Kuo. (2008) Treatment Strategies for Neurogenic Voiding Dysfunction. Tzu Chi Medical Journal 20:1, pages 35-39.
Crossref
Crossref
Arun Sahai, Christopher Dowson, Mohammad Shamim Khan & Prokar Dasgupta. (2008) EFFICACY AND COMPLICATIONS OF INTRADETRUSOR INJECTION WITH BOTULINUM TOXIN A IN PATIENTS WITH REFRACTORY IDIOPATHIC DETRUSOR OVERACTIVITY. BJU International 101:4, pages 515-516.
Crossref
Crossref